Tier 4 — mechanistic
Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization
NPJ cardiovascular health
2026
3(1):15
Bibliography
- PubMed
- PMID 41882153
- PubMed Central
- PMC13018313
- Trial registry
- View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
- Funding
- Reported funding sources: https://doi.org/10.13039/501100005847Health and Medical Research Fund. Grant and funder-role details are in the publication.
- Competing interests
- A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.
Study snapshot
| Design | Trial-signature, cohort and Mendelian-randomization analysis |
|---|---|
| Model | Human trial-derived proteomic/hormonal signature, cohort data and genetic summary data |
| Sample | Trial-derived signature plus UK Biobank and genetic datasets |
| Intervention | Proteomic/hormonal response signature; observational and Mendelian-randomization analyses |
| Duration | Secondary analysis; not a new long-term berberine intervention |
| Endpoints | Cardiac or vascular outcomes; Inflammatory biomarkers; Adverse events |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
